Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Total Current Liabilities: 2020-2025

Historic Total Current Liabilities for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to $10.8 million.

  • SAB Biotherapeutics' Total Current Liabilities rose 22.43% to $10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 22.43%. This contributed to the annual value of $8.0 million for FY2024, which is 26.21% down from last year.
  • According to the latest figures from Q3 2025, SAB Biotherapeutics' Total Current Liabilities is $10.8 million, which was up 1.09% from $10.7 million recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Total Current Liabilities registered a high of $26.5 million during Q4 2021, and its lowest value of $80,000 during Q1 2021.
  • Over the past 3 years, SAB Biotherapeutics' median Total Current Liabilities value was $9.7 million (recorded in 2025), while the average stood at $9.9 million.
  • In the last 5 years, SAB Biotherapeutics' Total Current Liabilities spiked by 23,988.30% in 2022 and then tumbled by 46.14% in 2023.
  • SAB Biotherapeutics' Total Current Liabilities (Quarterly) stood at $26.5 million in 2021, then slumped by 43.33% to $15.0 million in 2022, then dropped by 27.88% to $10.8 million in 2023, then dropped by 26.21% to $8.0 million in 2024, then rose by 22.43% to $10.8 million in 2025.
  • Its Total Current Liabilities was $10.8 million in Q3 2025, compared to $10.7 million in Q2 2025 and $9.7 million in Q1 2025.